• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Hetlioz (tasimelteon)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Hetlioz (tasimelteon)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Hetlioz (tasimelteon) is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms. The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non­ 24 is not known.

    Hetlioz is specifically indicated for the treatment of non-24-hour sleep-wake disorder in the totally blind.

    Hetlioz is supplied as a capsule for oral administration. The recommended dosage of Hetlioz is 20 mg per day taken before bedtime, at the same time every night. Because of individual differences in circadian rhythms, drug effect may not occur for weeks or months.

    Clinical Results

    FDA Approval
    The FDA approval of Hetlioz was based on two randomized, double blind, placebo controlled parallel groups studies (Study 1 and 2) in totally blind subjects with non-24-hour sleep-wake disorder (non-24). In study 1, 84 subjects (median age 54 years) were randomized to receive Hetlioz 20 mg or placebo, one hour prior to bedtime, at the same time every night for up to 6 months. Study 2 was a randomized withdrawal trial in 20 subjects (median age 55 years) that was designed to evaluate the maintenance of efficacy of Hetlioz after 12-weeks. Subjects were treated for approximately 12 weeks with Hetlioz 20 mg one hour prior to bedtime, at the same time every night. Subjects in whom the calculated time of peak melatonin level (melatonin acrophase) occurred at approximately the same time of day (in contrast to the expected daily delay) during the run-in phase were randomized to receive placebo or continue treatment with Hetlioz 20 mg for 8 weeks. Both studies evaluated the duration and timing of nighttime sleep and daytime naps via patient-recorded diaries. During Study 1, diaries were recorded for an average of 88 days during screening, and 133 days during randomization. During Study 2, diaries were recorded diaries were recorded for an average of 57 days during the run-in phase , and 59 days during the randomized withdrawl phase. Efficacy endpoints for nighttime total sleep time and daytime nap duration were based on the 25% of nights with the least nighttime sleep, and the 25% of days with the most daytime nap time. In both studies, treatment with Hetlioz resulted in a significant improvement, compared with placebo, for both of these endpoints. Study 1: Change from baseline for nighttime sleep time on 25% most symptomatic nights: 50 minutes increase for Hetlioz vs. 22 minutes for placebo; Change from baseline for daytime nap time on 25% most symptomatic days: -49 minute reduction for Hetlioz and -22 minutes for placebo. Study 2: Change from baseline for nighttime sleep time on 25% most symptomatic nights: -7 minutes for Hetlioz vs. -74 minutes for placebo; Change from baseline for daytime nap time on 25% most symptomatic days: -9 minute reduction for Hetlioz versus 50 minute increase for placebo.

    Side Effects

    Adverse events associated with the use of Hetlioz may include, but are not limited to, the following:

    • headache
    • increased alanine aminotransferase
    • nightmares or unusual dreams
    • upper respiratory or urinary tract infection

    Mechanism of Action

    Hetlioz (tasimelteon) is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms. The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non­ 24 is not known.

    Additional Information

    For additional information regarding Hetlioz or non­24-hour sleep-wake disorder, please visit the Hetlioz web page.

    Approval Date: 2014-01-01
    Company Name: Vanda Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing